AstraZeneca Annual Report and Form 20-F Information 2008

Notes to the Financial Statements (Group)

• 21 Dividends to shareholders
• 22 Acquisitions of business operations
• 23 Post-retirement benefits
• 24 Employee costs and share option plans for employees
• 25 Commitments and contingent liabilities
• 26 Leases
• 27 Statutory and other information

21 Dividends to shareholders

	2008 Per share	2007 Per share	2006 Per share	2008 $m	2007 $m	2006 $m
Final	$1.350	$1.230	$0.920	1,967	1,885	1,453
Interim	$0.550	$0.520	$0.490	800	773	764
	$1.900	$1.750	$1.410	2,767	2,658	2,217

The second interim dividend, to be confirmed as final, is $1.50 per share and $2,171m in total. This will be payable on 16 March 2009.

On payment of the dividends, exchange gains of $28m (2007: gains of $17m; 2006: losses of $3m) arose. These exchange gains and losses are included in Note 2.

Back to the top